Watchdogs want FDA number in DTC ads

Share this article:
Arguing that most Americans don't know about the FDA's adverse events reporting program, Consumers Union said DTC ads should include a toll-free number that patients can use to report side effects to the FDA.

The nonprofit presented the agency with a petition to that effect including 56,000 signatures. Consumer Reports, a publication of the group, released the results of a poll finding that of all respondents who had ever taken a prescription drug, 16% had experienced a serious side effect, but only 35% of all respondents were aware that side effects could be reported to FDA. 

Four out of five respondents reported seeing or hearing a drug ad within the past 30 days – nearly all on TV. Asked if ads should include reporting information, 87% said TV spots should, and 90% said print ads should do the same. 

A requirement that print ads – but not TV ads – include reporting info was included in last year's FDA Amendments Act, the group noted. Congress ordered a study on the feasibility of such a condition for TV ads as well, but the study, due at the end of March, has not been completed. 

“You can't turn on a TV today without seeing a drug ad, but those ads never mention that consumers should be reporting serious drug side effects to the FDA,” said Consumers Union campaign coordinator Liz Foley in a statement. “What better way for the FDA to let consumers know how to report serious problems with their medications than putting a toll-free number and website in all those drug ads we're bombarded by each day?”
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

New lipid agents are high on potency, low on doc awareness

New lipid agents are high on potency, low ...

The new PCSK9 class of cholesterol-lowering antibodies continues to look promising, but many doctors—particularly PCPs—have never even heard of the experimental drugs.

Novartis may have game-changing drug

Novartis may have game-changing drug

Key opinion leaders indicate they are ready to embrace Novartis's experimental heart failure medication LCZ696. Such a move could upend heart failure treatment protocols.

Five things for pharma marketers to know: Tuesday, September 2

Five things for pharma marketers to know: Tuesday, ...

Sanofi and Regeneron unveil Phase-III results of their PCSK9; Merck will present data on its anti-PD-1 at the end of this month; WSJ op/ed suggests US should lead fight against ...